ArticleJournal of the Endocrine Society2021
Thyroid Eye Disease: Navigating the New Treatment Landscape.
Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.BMJ open ophthalmology · 2024Pooled it
- Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.The Journal of clinical endocrinology and metabolism · 2023Trial
- Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease.The Journal of clinical endocrinology and metabolism · 2026Review
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
- Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- A Comprehensive Review of Selenium as a Key Regulator in Thyroid Health.Biological trace element research · 2025Review
- Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study.Endocrine connections · 2025Article
- Review
- Puzzling Late Relapse of Thyroid Eye Disease: A Case Series.JCEM case reports · 2025Article
- Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database.Clinical endocrinology · 2025Article
- Study on the correlation between serum IgG4/IgG levels and the development of Graves' ophthalmopathy.Scientific reports · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- The role of mycophenolate mofetil in the therapy of thyroid eye disease.Therapeutic advances in endocrinology and metabolism · 2025Review
- Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.Ophthalmology · 2024Observational
- Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.Cureus · 2023Review
- A 46-Year-Old Woman with a 4-Year History of Graves Disease, with Severe Corticosteroid-Unresponsive Thyroid Eye Disease, Successfully Treated with Tocilizumab.The American journal of case reports · 2023Article
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Thyroid dermopathy responds to teprotumumab therapy.Endocrinology, diabetes & metabolism case reports · 2022Article
- Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid eye disease (TED) is a complex inflammatory disease that can have a long clinical course with sight-threatening and debilitating ocular sequelae. Until recently, there were limited therapeutic options available. In the last decade we have gained a deeper understanding of the underlying pathophysiology, which has led to the development of novel effective targeted therapies. This article discusses the challenges encountered in the clinical evaluation and treatment of TED patients, with the goal to empower endocrinologists and ophthalmologists to work together to provide effective multidisciplinary care. We will review recommendations of past clinical guidelines around evaluation and management of TED patients, discuss the randomized controlled trials of new biologic therapies, and explore how to navigate the emerging therapeutic landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.